Navigation Links
Molecular imaging holds promise for early intervention in common uterine cancer
Date:10/1/2009

Reston, Va.A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

"Endometrial carcinoma is one of the most common female malignant tumors," says Hidehiko Okazawa, M.D., Ph.D., professor in the division of medical imaging at the biomedical imaging research center at the University of Fukui in Japan and one of the lead researchers of the study. "The method of positron emission tomography (PET) imaging we used in the study is noninvasive, and it has tremendous potential to save women with endometrial carcinoma from undergoing unnecessary operations and biopsies that could sabotage their reproductive potential."

If the disease is caught early enough, the five-year survival rate is higher than 90% for patients with endometrial carcinoma. PET imaging may provide physicians with a tool that lets them recognize the extent of the disease before it reaches advanced stages.

This study shows that PET is a promising molecular imaging technique for personalized therapy. Molecular imaging and nuclear medicine provide the possibility of determining the invasiveness and aggressiveness of malignant tumors in the uterus earlier on, before disease progresses. With this technique, physicians gain the advantage of a more precise diagnosis along with the ability to better predict the tumor's growth patterns and plan for the most appropriate therapeutic treatment strategy.

"The article in the JNM from Dr. Tsujikawa and colleagues provides an example of the unique capacity of molecular imaging to measure in vivo cancer biology," says David A. Mankoff, M.D., Ph.D., professor of radiology, medicine and bioengineering at the University of Washington and Seattle Cancer Care Alliance in Seattle. "Most notably, it shows how imaging multiple facets of tumor phenotypein this case, estrogen receptor expression and glucose metabolismcan provide insight into the clinical behavior of cancer. The broad implication of this study, and other similar studies that have tested PET and molecular imaging to characterize cancer characteristics, is that imaging can help direct cancer patients toward optimized, individualized treatments."

In the study, the researchers used a specialized form of PET imaging called "estrogen receptor expression imaging" for 22 patients with endometrial adenocarcinoma and nine patients with endometrial hyperplasia (a thickening of the uterine lining that is a risk factor for developing endometrial cancer) to evaluate diagnostic accuracy. All patients underwent preoperative PET scans with 18F-fluoroestradiol (18F-FES)a tracer that has been successfully used in diagnosing breast cancerand 18F-fluorodeoxyglucose (18F-FDG) to compare differences in tracer accumulation.

The researchers confirmed that endometrial carcinoma reduces estrogen dependency with accelerated glucose metabolism as it progresses to a higher stage or grade. By combining the two tracers, researchers were able to use a new index of uptake ratio that can better predict pathologic stages and aggressiveness of tumors. The results of the study were encouraging, with the combined techniques having 86% accuracy.

For endocrine-related tumors (including endometrial cancer), tumors vary from well-differentiated and close in character to the tissue of origin to poorly differentiated tumors, which are aggressive and bear less resemblance to the tissue of origin. The well-differentiated tumors tend to be more slow-growing and less aggressive than poorly differentiated tumors. They also retain their endocrine function and/or responsiveness.

For endometrial cancer, estrogen receptor expression is related to endocrine responsiveness and indicated by FES uptake. Poorly differentiated tumors often have increased and abnormal breakdown of glucose, indicated by FDG. The combination of the two, as indicated by the study, was better than either alone at indicating the aggressiveness of the tumor.

Personalized cancer therapy involves treatment that is individualized for patients based on patient characteristics and the tumor's biology. By studying the tumor's properties, physicians can predict the tumor's path and formulate the best strategy for treating the disease.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Reportlinker Adds Whos Doing What in Molecular Diagnostics? - Kalorama / Emmes Survey of US Laboratories Report
2. Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report
3. News from the Latest Issue of Molecular Medicine
4. Inner workings of molecular thermostat point to pathways to fight diabetes, obesity
5. Team reveals molecular mechanism underlying a form of diabetes
6. Cost Effective Solution for Patient Testing: Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy
7. Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents
8. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
9. Dynamic molecular mechanism to keep brain activity stable
10. Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
11. News from the Latest Issue of Molecular Medicine Kicking The Habit - It's In The Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
(Date:3/29/2017)... Baton Rouge, Louisiana (PRWEB) , ... March 29, ... ... trademarked HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, ... campaign at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients ... in Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The ... traditional orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system ...
(Date:3/29/2017)... ARNOLD, Md., and MINNETONKA, Minn. (PRWEB) , ... ... ... for the development of medical office buildings (MOBs) and other outpatient facilities, and ... research project to look exclusively at those questions, Revista and Healthcare Real Estate ...
(Date:3/29/2017)... ... 29, 2017 , ... An inventor from Raynham, Mass., knows ... in conjunction with my braces always rubbed against the inside of my cheeks, ... this problem." The O.B.S. was the result of his brainstorming. , This patent-pending ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... Centers & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected ... The Untapped Proton Therapy Market for South Korea ... Proton Therapy plays an important role in delivering comprehensive cancer care ...
(Date:3/29/2017)... -- The leader in accelerated orthodontics, OrthoAccel ® Technologies, ... Manal Ibrahim , Kenji Ojima , ... featured microlecture presenters at the AcceleDent ® booth ... Annual Session, April 21-25, 2017. Orthodontists and their staff ... 11:20 a.m. On the opening morning of AAO exhibitions, ...
(Date:3/29/2017)... March 29, 2017  Maxor National Pharmacy Services, LLC ... it has named Leah Bailey as General ... of the company. With more than 13 ... 8 years focused on health care, Bailey joins the ... at Prime, Bailey advised the PBM, Specialty, and Mail ...
Breaking Medicine Technology: